Benitec Biopharma Analyst Ratings
Benitec Biopharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/26/2023 | 90.48% | JMP Securities | $4 → $6 | Maintains | Market Outperform |
06/26/2023 | 26.98% | JMP Securities | → $4 | Reiterates | Market Outperform → Market Outperform |
05/18/2023 | 26.98% | JMP Securities | $4 → $4 | Reiterates | Market Outperform → Market Outperform |
10/18/2022 | 26.98% | JMP Securities | → $4 | Initiates Coverage On | → Market Outperform |
09/23/2022 | 26.98% | HC Wainwright & Co. | $10 → $4 | Maintains | Buy |
02/17/2022 | 217.46% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
10/05/2020 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
09/26/2023 | 90.48% | JMP 證券 | 4 美元 → 6 美元 | 維護 | 市場表現跑贏大盤 |
06/26/2023 | 26.98% | JMP 證券 | → 4 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
05/18/2023 | 26.98% | JMP 證券 | 4 美元 → 4 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
2022 年 10 月 18 日 | 26.98% | JMP 證券 | → 4 美元 | 啓動覆蓋範圍開啓 | → 市場跑贏大盤 |
09/23/2022 | 26.98% | HC Wainwright & Co. | 10 美元 → 4 美元 | 維護 | 購買 |
02/17/2022 | 217.46% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2020 年 5 月 10 日 | — | 拉登堡塔爾曼 | 降級 | 買入 → 中性 |
What is the target price for Benitec Biopharma (BNTC)?
貝尼特克生物製藥(BNTC)的目標價格是多少?
The latest price target for Benitec Biopharma (NASDAQ: BNTC) was reported by JMP Securities on September 26, 2023. The analyst firm set a price target for $6.00 expecting BNTC to rise to within 12 months (a possible 90.48% upside). 4 analyst firms have reported ratings in the last year.
JMP Securities於2023年9月26日公佈了貝尼特克生物製藥(納斯達克股票代碼:BNTC)的最新目標股價。該分析公司將目標股價定爲6.00美元,預計BNTC將在12個月內上漲至90.48%(可能上漲90.48%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Benitec Biopharma (BNTC)?
貝尼特克生物製藥(BNTC)的最新分析師評級是多少?
The latest analyst rating for Benitec Biopharma (NASDAQ: BNTC) was provided by JMP Securities, and Benitec Biopharma maintained their market outperform rating.
Benitec Biopharma(納斯達克股票代碼:BNTC)的最新分析師評級由JMP Securities提供,Benitec Biopharma維持其市場跑贏大盤評級。
When is the next analyst rating going to be posted or updated for Benitec Biopharma (BNTC)?
Benitec Biopharma(BNTC)的下一份分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Benitec Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Benitec Biopharma was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.
分析師在進行了廣泛的研究後得出了股票評級,包括閱讀公開財務報表,與貝尼泰克生物製藥公司的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。Benitec Biopharma的最新評級是在2023年9月26日提交的,因此你應該預計下一個評級將在2024年9月26日左右公佈。
Is the Analyst Rating Benitec Biopharma (BNTC) correct?
Benitec Biopharma(BNTC)的分析師評級是否正確?
While ratings are subjective and will change, the latest Benitec Biopharma (BNTC) rating was a maintained with a price target of $4.00 to $6.00. The current price Benitec Biopharma (BNTC) is trading at is $3.15, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但貝尼特克生物製藥(BNTC)的最新評級保持不變,目標股價爲4.00美元至6.00美元。Benitec Biopharma(BNTC)目前的交易價格爲3.15美元,超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。